From the helm: Immutep’s (ASX:IMM) Executive Director & CEO, Marc Voigt

Jessica Amir
August 26, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients’ tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results…

In this video Marc discusses:

  • (0:40) IMM’s progress: the year that was, and the year ahead
  • (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
  • (2:29) Its unique discovery in immunotherapy – which spells new opportunities
  • (4:02) Key catalysts that could drive share price growth
  • (6:00) Fund managers who bought into IMM recently – and how funds raised will be spent

Weekly Wrap 3 December

Sophia Mavridis
December 3, 2021

Morning Bell 2 December

Paulina Peters
December 2, 2021

Morning Bell 1 December

Sophia Mavridis
December 1, 2021

Morning Bell 30 November

Paulina Peters
November 30, 2021

Morning Bell 29 November

Sophia Mavridis
November 29, 2021

Weekly Wrap 26 November

Sophia Mavridis
November 26, 2021

Morning Bell 25 November

Paulina Peters
November 25, 2021

Morning Bell 24 November

Sophia Mavridis
November 24, 2021

Morning Bell 23 November

Paulina Peters
November 23, 2021

Morning Bell 22 November

Sophia Mavridis
November 22, 2021

Weekly Wrap 19 November

Sophia Mavridis
November 19, 2021

Morning Bell 18 November

Paulina Peters
November 18, 2021